-
1
-
-
34249856499
-
New antiplatelet strategies in atherothrombosis and their indications
-
Fontana P, Reny JL. New antiplatelet strategies in atherothrombosis and their indications. Eur J Vasc Endovasc Surg 2007; 34: 10-17.
-
(2007)
Eur J Vasc Endovasc Surg
, vol.34
, pp. 10-17
-
-
Fontana, P.1
Reny, J.L.2
-
2
-
-
70349204630
-
Effect of pharmaceutical interventions targeting thromboxane receptors and thromboxane synthase in cardiovascular and renal diseases
-
Sakariassen KS, Alberts P, Fontana P, Mann J, Bounameaux H, Sorensen AS. Effect of pharmaceutical interventions targeting thromboxane receptors and thromboxane synthase in cardiovascular and renal diseases. Future Cardiol 2009; 5: 479-93.
-
(2009)
Future Cardiol
, vol.5
, pp. 479-493
-
-
Sakariassen, K.S.1
Alberts, P.2
Fontana, P.3
Mann, J.4
Bounameaux, H.5
Sorensen, A.S.6
-
3
-
-
0034691261
-
Cardiovascular responses to the isoprostanes iPF(2alpha)-III and iPE(2)-III are mediated via the thromboxane A(2) receptor in vivo
-
Audoly LP, Rocca B, Fabre JE, Koller BH, Thomas D, Loeb AL, Coffman TM, FitzGerald GA. Cardiovascular responses to the isoprostanes iPF(2alpha)-III and iPE(2)-III are mediated via the thromboxane A(2) receptor in vivo. Circulation 2000; 101: 2833-40.
-
(2000)
Circulation
, vol.101
, pp. 2833-2840
-
-
Audoly, L.P.1
Rocca, B.2
Fabre, J.E.3
Koller, B.H.4
Thomas, D.5
Loeb, A.L.6
Coffman, T.M.7
FitzGerald, G.A.8
-
4
-
-
0032582678
-
Direct inhibition of cyclooxygenase-1 and -2 by the kinase inhibitors SB 203580 and PD 98059. SB 203580 also inhibits thromboxane synthase
-
Borsch-Haubold AG, Pasquet S, Watson SP. Direct inhibition of cyclooxygenase-1 and -2 by the kinase inhibitors SB 203580 and PD 98059. SB 203580 also inhibits thromboxane synthase. J Biol Chem 1998; 273: 28766-72.
-
(1998)
J Biol Chem
, vol.273
, pp. 28766-28772
-
-
Borsch-Haubold, A.G.1
Pasquet, S.2
Watson, S.P.3
-
5
-
-
0024588409
-
Measurements of platelet interaction with components of the vessel wall in flowing blood
-
Sakariassen KS, Muggli R, Baumgartner HR. Measurements of platelet interaction with components of the vessel wall in flowing blood. Methods Enzymol 1989; 169: 37-70.
-
(1989)
Methods Enzymol
, vol.169
, pp. 37-70
-
-
Sakariassen, K.S.1
Muggli, R.2
Baumgartner, H.R.3
-
6
-
-
0015861774
-
Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction
-
Cheng Y, Prusoff WH. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 1973; 22: 3099-108.
-
(1973)
Biochem Pharmacol
, vol.22
, pp. 3099-3108
-
-
Cheng, Y.1
Prusoff, W.H.2
-
7
-
-
0023137593
-
Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs
-
Reilly IA, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 1987; 69: 180-6.
-
(1987)
Blood
, vol.69
, pp. 180-186
-
-
Reilly, I.A.1
FitzGerald, G.A.2
-
8
-
-
0347985760
-
Costimulation of the Gi-coupled ADP receptor and the Gq-coupled TXA2 receptor is required for ERK2 activation in collagen-induced platelet aggregation
-
Roger S, Pawlowski M, Habib A, Jandrot-Perrus M, Rosa JP, Bryckaert M. Costimulation of the Gi-coupled ADP receptor and the Gq-coupled TXA2 receptor is required for ERK2 activation in collagen-induced platelet aggregation. FEBS Lett 2004; 556: 227-35.
-
(2004)
FEBS Lett
, vol.556
, pp. 227-235
-
-
Roger, S.1
Pawlowski, M.2
Habib, A.3
Jandrot-Perrus, M.4
Rosa, J.P.5
Bryckaert, M.6
-
9
-
-
0033925020
-
The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis
-
Cayatte AJ, Du Y, Oliver-Krasinski J, Lavielle G, Verbeuren TJ, Cohen RA. The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. Arterioscler Thromb Vasc Biol 2000; 20: 1724-8.
-
(2000)
Arterioscler Thromb Vasc Biol
, vol.20
, pp. 1724-1728
-
-
Cayatte, A.J.1
Du, Y.2
Oliver-Krasinski, J.3
Lavielle, G.4
Verbeuren, T.J.5
Cohen, R.A.6
|